When aiming for a billion-dollar outcome, a 10-20% valuation difference in early funding rounds becomes negligible. The priority should be securing a long runway with as much capital as possible when it's available, as this enables the execution required to reach a massive exit.
ImCheck sold to Ibsen over larger pharma giants because the deal's size relative to Ibsen guarantees commitment. For a top-tier pharma, a $400M upfront payment can be an acceptable write-off if strategies shift, posing a greater risk of the asset being deprioritized post-acquisition.
To strengthen its clinical case without a randomized trial, ImCheck created an external control arm using historical data. This "synthetic" comparison provided strong efficacy signals that de-risked the program, supported a seamless Phase 2/3 FDA plan, and boosted their leverage in M&A discussions.
Despite promising data from leaders like Moderna, many cancer vaccine companies struggle to raise capital. This is driven by a perception that big pharma is largely uninterested in the modality, preferring to invest in and acquire assets in hotter areas like ADCs and in-vivo CAR therapies.
The key takeaways from the major ASCO oncology conference are a continued strong push for Antibody-Drug Conjugates (ADCs), the rise of translational AI, and a strategic shift towards pan-tumor approaches that can address a wide panel of cancers rather than focusing on a single indication.
The initial hope for a revolution across many immune checkpoints has faded. With most targets outside of PD-1 failing to deliver, investors and pharma have grown fatigued. This disappointment has accelerated the industry's pivot towards other modalities like ADCs and cell therapies.
To attract quality investment, a biotech must present a complete package. A great scientific idea alone is insufficient. It requires initial supporting data to validate the concept and a talented execution-focused team to transform that data into a clinical asset. All three are essential.
Historically, the French biotech scene was held back by a lack of large domestic investment funds. This has changed significantly, with local VCs now raising large funds capable of leading nine-figure rounds. This growing financial muscle allows French biotechs to scale effectively within their own ecosystem.